Clinical Trial Update: Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant) [Phase 1]

View source ↗

Summary

Phase 1 study of an H5N1 influenza vaccine using reverse genetic reassortant has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pandemic Influenza

Drugs mentioned

• H5N1 influenza vaccine (reverse genetic reassortant)

Snippet

Sponsor: Alachua Government Services, Inc. | Conditions: Influenza, Pandemic Influenza | Phase 1 | Status: COMPLETED